================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   ----------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): November 7, 2005

                               Immunomedics, Inc.
             ------------------------------------------------------
             (Exact Name of Registrant as Specified in Its Charter)

             Delaware                 000-12104             61-1009366
   ----------------------------      ------------       -------------------
   (State or Other Jurisdiction      (Commission        (I.R.S.  Employer
         of Incorporation)           File Number)       Identification No.)

    300 American Road, Morris Plains, New Jersey              07950
    --------------------------------------------           ----------
      (Address of Principal Executive Offices)             (Zip Code)

       Registrant's telephone number, including area code: (973) 605-8200

                                 Not Applicable
          -------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

         Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities
     Act (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange
     Act (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================



ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

         On November 7, 2005, Immunomedics, Inc., a Delaware corporation (the
"Company"), issued a press release to report the Company's financial results for
the quarter ended September 30, 2005. The full text of the press release is
attached to this current report on Form 8-K as Exhibit 99.1.

ITEM 9.01.    FINANCIAL STATEMENTS AND EXHIBITS.

       (c)    Exhibits:

              99.1   Press release of Immunomedics, Inc. dated November 7, 2005,
                     reporting its financial results.

         * The information in this Form 8-K shall not be deemed to be "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange
Act"), or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933
or the Exchange Act, except as expressly set forth by specific reference in such
filing.

                                       -2-


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

Date:  November 7, 2005                IMMUNOMEDICS, INC.


                                       By: /s/ Cynthia L. Sullivan
                                           -------------------------------------
                                           Cynthia L. Sullivan
                                           President and Chief Executive Officer

                                       -3-